News Story: Full Text
Sponsored By
AbbVie
Please Click On The Above Banner For More Details
Braintumor Website

 

Oncolytics Phase I/II Reolysin Glioma Trial Begun


Posted on: 07/15/2002

July 8, 2002

Oncolytics Phase I/II Reolysin Glioma Trial Begun


Oncolytics Biotech has begun a phase I/II brain cancer clinical trial with Reolysin, a drug developed from the naturally occurring reovirus. The company plans to enroll about 38 patients who have been diagnosed with recurrent malignant glioma, a condition often characterized by activation of the RAS pathway; Reolysin has been shown to infect and kill malignant cells that harbor such mutations.

In the phase I part of the phase I/II trial, scientists will enroll patients with various recurrent malignant glioma and test different doses of Reolysin. In the phase II portion, patients with recurrent glioblastoma multiforme will be treated with doses of Reolysin as determined by the results of the phase I study.

In past research, scientists found that that 20 of 23 mice treated with one injection of reovirus experienced benefits including complete tumor regression and had a statistically significant increase in survival. The reovirus killed cancer cells from 19 of 24 established glioma cell lines and from all nine glioma surgical specimens.
Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740